Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Front Endocrinol (Lausanne) 14(12):735824 [DOI] [PMC free article] [PubMed] [Google Scholar] 78.Cheng L, Hu Y, Li YY, Cao X, Bai N, Lu TT, Li GQ, Li N, Wang AN, Mao XM (2019) Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials
(34) Given the increased risk of sarcopenia, osteoporosis, and frailty in older adults, future research should explore the long-term effects of GLP-1 receptor agonists on musculoskeletal health in this population, alongside their established systemic benefits
Bone (2002) 30(1):30713.10.1016/S8756-3282(01)00662-7 17 Nuche-BerenguerBMorenoPEsbritPDapiaSCaeiroJRCancelasJet alEffect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states
GLP-1 is derived from the PG precursor, which is a class of highly efficient incretins released by the body in response to nutrient intake
US$ 29.90
US$ 25.57
US$ 28.05
US$ 20.90
US$ 25.55
US$ 27.49
